Cannabis, Cognition and Mental Health: What the Evidence Shows
Cannabis can produce short-term changes in memory, attention, decision-making and reward processing. The size and persistence of those effects vary with factors such as THC dose, frequency of use, age of initiation, sex, genetic vulnerability and whether a person has cannabis-use disorder.
THC, cannabis’s main intoxicating compound, acts on the brain’s endocannabinoid system, particularly through cannabinoid type 1 receptors. These receptors are widely distributed in regions involved in memory, attention, emotion, motivation and cognitive control, including the prefrontal cortex, hippocampus, amygdala and striatum.
A 2018 meta-analysis of functional neuroimaging studies found that cannabis users showed reduced activity in parts of the anterior cingulate and dorsolateral prefrontal cortex—regions associated with cognitive control and attention—alongside increased activity in the striatum, which is involved in reward processing. Because the analysis combined observational imaging studies, however, it could identify patterns associated with cannabis use but could not establish that cannabis caused every observed brain difference.
The clearest cognitive effects occur during intoxication. Research has consistently linked acute cannabis exposure with poorer episodic and working memory, slower information processing and reduced executive control. Longer-term findings are more complicated. A 2020 meta-analysis of regular cannabis users found small deficits in executive function, learning and memory, and overall cognition, with larger differences in decision-making. The researchers also emphasized that many studies were limited by differences in cannabis exposure, abstinence periods, education, mental health and the use of other substances.
People with cannabis-use disorder—characterized by difficulty controlling use despite harmful consequences—may be particularly vulnerable. Compared with occasional or non-users, they often perform less well on memory and decision-making tasks. Some evidence suggests that cognitive performance improves after sustained abstinence, while other studies report residual differences. This mixed picture means that persistent impairment cannot automatically be attributed to cannabis alone.
Age of initiation is an important consideration. Adolescence is a period of substantial brain development, and studies have associated cannabis use during this period with poorer executive functioning, memory and educational outcomes. Yet pre-existing differences may also play a role: young people who begin using cannabis may already differ from non-users in attention, mental health, family environment or genetic risk. A review of adolescent research concluded that cognitive differences can improve with abstinence and that the evidence for lasting brain changes remains inconsistent.
Sex-related differences have also been reported, but the findings are not settled. Some studies have linked cannabis use in males with poorer visual memory and in females with greater difficulties in attention or executive control. A 2025 systematic review of acute cognitive effects, however, found limited and inconsistent evidence for meaningful sex differences. More research that measures hormonal factors, dose, potency and patterns of use is needed.
Cannabis may influence motivation and the experience of reward as well as performance on cognitive tests. A systematic review of reward processing found evidence of greater anhedonia—the reduced ability to experience pleasure—in some adolescent cannabis users, along with indications of altered reward learning and blunted neural responses to rewards. These findings do not support the simple stereotype that every cannabis user becomes apathetic or unmotivated. Motivation is affected by depression, anxiety, dependence, social circumstances and other factors, and the direction of the relationship may be reciprocal.
This was illustrated during the COVID-19 lockdown period. In a study of adolescents and adults, apathy and anhedonia increased during lockdown, with the largest increases among participants with cannabis dependence. Adolescent users reported more anhedonia than age-matched controls, while adult users did not consistently differ from adult non-users. The study was observational, so it could not determine whether cannabis caused the symptoms or whether people experiencing reduced motivation were more likely to use cannabis.
Psychosis is another area of concern, particularly for adolescents and people with a personal or family vulnerability to psychotic disorders. Cannabis use has been associated with psychotic-like experiences and an increased risk of psychosis, with risk generally higher among people who begin early, use frequently or consume high-potency products. A systematic review and meta-analysis of adolescent cannabis use found an association with later psychosis and earlier onset of psychotic illness. The relationship is complex, however: shared genetic and environmental vulnerabilities may contribute, and cannabis may precipitate or worsen symptoms in people who are already susceptible rather than independently causing schizophrenia in everyone who uses it.
Dopamine, glutamate and the endocannabinoid system are among the biological pathways being investigated to explain these effects. At present, they offer plausible mechanisms, not a complete explanation. The evidence is strongest for temporary impairment during intoxication and for elevated psychosis risk in vulnerable, frequent or early-onset users. The extent to which prolonged use produces permanent cognitive or psychological changes remains uncertain.
For young people and anyone with a personal or family history of psychosis, the potential risks deserve particular attention. Future studies will need better measures of THC potency and dose, longer follow-up, more diverse participants and stronger controls for pre-existing differences before researchers can determine which effects are reversible and which may persist.
